Intralytix Receives USDA, NIFA Phase III SBIR Grant To Optimize Application of Its Salmonella-Targeting Bacteriophage Preparation SalmoFresh™ at Poultry and Meat Producers

Intralytix, Inc., announced today that it has received a SBIR Phase III grant (Award No. 2023-70439-39191) from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA)'s Meat and Poultry Processing Research and Innovation Program, to optimize SalmoFresh™ application at small and medium poultry and meat producers.

Intralytix Launches Phase 1/2a Phage Therapy Trial to Prevent Illness Caused by Shigella

Intralytix, Inc. today announced the launch of a Phase 1/2a clinical trial to assess the safety and efficacy of Intralytix phage therapy product ShigActive™ to prevent or reduce the severity of Shigella infections.

Intralytix receives Phase II Fast Track NIH SBIR contract to continue development of a universal, scale-independent AI-based platform for manufacturing high titer bacteriophage preparations for clinical applications.

Intralytix, Inc. announced today that it has received a Phase II contract in the amount of $1,498,045. This contract is made through the Small Business Innovation Research (SBIR) program from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This project is the continuation of a successfully completed NIAID-funded Phase I contract.

Intralytix Granted Clearance by the FDA for an Investigational New Drug Application for Phase 1/2a Clinical Trials for Vancomycin Resistant Enterococci (VRE)-targeting Phage Preparation

Intralytix, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product VRELysin™, a bacteriophage preparation to manage colonization of vancomycin resistant Enterococcus (VRE) in the human gut.

AB Agri has partnered with US biotechnology company Intralytix to explore the use of bacteriophages – the natural viruses of bacteria – in animal feed as an alternative to antibiotics and other drugs

Both companies believe there is potential to use the abundant probiotic microorganisms to intensify natural processes, thereby tackling bacteria and boosting gut health without the need for broad spectrum antibiotic medication.

Intralytix Receives FDA Clearance for Investigational New Drug Application for Phase 1/2a Clinical Trials for Shigella-targeting Phage Preparation

Intralytix, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product ShigActive™, a bacteriophage preparation to manage Shigella infections in humans.

Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology

Intralytix, Inc. announced today that its food safety product, CampyShield™, has received GRAS (Generally Recognized as Safe) recognition from the Food and Drug Administration (FDA), GRAS No: GRN 000966.

Intralytix receives Fast Track NIH SBIR contract to develop a universal, scale-independent AI-based platform for manufacturing high titer bacteriophage preparations for clinical applications

Intralytix, Inc. announced today that it has received a Phase I award in the amount of $299,672 with an option for a Phase II award in the amount of $1,498,045. This award is made through the Small Business Innovation Research (SBIR) program under a Fast-Track Phase I / Phase II program providing for up to $1.8 million from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).

Intralytix Receives SBIR Grant to Develop Phage Preparation for Reducing Vibrio parahaemolyticus Contamination of Foods

Intralytix, Inc. announced today that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Food and Agriculture (NIFA), an agency of the U.S. Department of Agriculture (USDA), for the development of a phage biocontrol solution for Vibrio parahaemolyticus in various food products, including seafood.

Intralytix awarded patent by USPTO for novel Shigella bacteriophages and their uses

Intralytix, Inc. announced today that it has been issued a patent by the U.S. Patent & Trademark Office (USPTO) covering its Shigella bacteriophages and their various applications.

Intralytix enters into CRADA with the U.S. Army Combat Capabilities Development Command Soldier Center

Intralytix, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Soldier Center (CCDC SC) in Natick, Massachusetts. The CRADA will focus on developing a dehydration process for bacteriophage cocktails, for use as a non-chemical and environmentally friendly food safety intervention and mitigation strategy for bacterial pathogens in fresh military procured food items.

Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans

Intralytix, Inc. announced today that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella.

Intralytix Receives FDA Regulatory Clearance for Expanded Use in Red Meat for Phage-Based Salmonella Technology

Intralytix, Inc. announced today that its food safety product, SalmoFresh™, has been granted a supplement to its GRAS (Generally Recognized As Safe) recognized status from the Food and Drug Administration (FDA), which expands the use of SalmoFresh™ to ready-to-eat and raw red meat carcasses, subprimals and trimmings.

Intralytix Receives FDA Regulatory Clearance and Expanded Use, Including in Ground Beef, for Phage-Based E. coli Food Safety Product

Intralytix, Inc. announced today that its broader acting and expanded use food safety product, EcoShield PX™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA) for elimination of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli (STEC) in many foods, including ground beef.

Intralytix Enters Into Joint Collaboration Agreement with the Eliava Foundation and Ferring Pharmaceuticals

Intralytix announces joint collaboration agreement to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine and Women's Health.

Intralytix Acquires Site for New Headquarters

Intralytix, Inc. announced today that it has closed on the acquisition of a 33,000 sq. ft. building in Columbia, Maryland. The facility, located in the Columbia Gateway Community, will serve as the Company's new headquarters.

Intralytix Receives FDA clearance to initiate Phase I / IIa clinical trials

Intralytix, Inc. announced today that it received clearance from the Food and Drug Administration (FDA) to initiate Phase I / IIa clinical trials at Mount Sinai hospital in New York, NY.

Lesaffre invests in Intralytix, a US biotechnology company

Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize phage-based products.

Intralytix Receives FDA Regulatory Clearance for Phage-Based Shigella Technology

Intralytix, Inc. announced today that its latest food safety product, ShigaShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

Intralytix, Inc. and Ferring Pharmaceuticals partner to develop bacteriophage treatments

Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.

Intralytix Receives USDA, NIFA Phase II SBIR Grant To Develop A Phage-Based Application To Protect Hatchery-Raised Oysters From The Bacterial Pathogens Vibrio tubiashii and Vibrio coralliilyticus

Intralytix, Inc., announced today that the company has received a SBIR Phase II grant from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA).

Intralytix and Ferring Pharmaceuticals Collaborate In Novel Bacteriophage-Based IBD Drug Development Project

Intralytix, Inc., announced today that it has entered into a collaboration agreement with Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group headquartered in St. Prex, Switzerland.

Intralytix Receives Additional Regulatory Approval For ListShield™ - Phage-Based Food Safety Product Effective Against Listeria monocytogenes

Intralytix, Inc. announced today that its food safety product, ListShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

Intralytix Wins USDA Grant To Develop A Phage-Based Application To Protect Hatchery-Raised Oysters From The Bacterial Pathogen, Vibrio tubiashii

Intralytix, Inc. announced today that the company has received a SBIR Phase I grant from the U.S. Department of Agriculture (U.S.D.A.) to develop a bacteriophage (or phage) cocktail effective against the shellfish pathogen Vibrio tubiashii.

Intralytix Wins Regulatory Approval For Phage-Based Food Safety Product Effective Against Salmonella

Intralytix, Inc. announced today that its latest food safety product, SalmoFresh™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

Intralytix Signs Multiple Project Collaboration Agreement with Procter & Gamble

Intralytix, Inc. announced today that it has entered into a Multiple Project Collaboration Agreement ("MPCA") with The Procter & Gamble Company (NYSE:PG).

Intralytix Awarded Grant For Managing Salmonella in Food

Intralytix, Inc. announced today that it has been awarded a grant under a National Institute of Food And Agriculture (NIFA) / United States Department of Agriculture (USDA) Small Business Innovative Research (SBIR) Grants Program.

Intralytix Completes Regulatory Clearance for Phage-Based E. coli Food Safety Technology

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for EcoShield™.

Intralytix Receives Follow-On Army Contract To Develop A Phage-Based Probiotic To Manage Shigella Infections

Intralytix, Inc. announced today that it has received a U.S. Army Phase II STTR contract supporting the further development of a bacteriophage-based probiotic preparation for managing Shigella infections.

Intralytix's CSO Appointed Editor-In-Chief of New Phage Journal

Intralytix, Inc. announced today that its Chief Scientific Officer, Dr. Alexander Sulakvelidze, has been appointed Editor-In-Chief of a new scientific journal called "Bacteriophage."

Intralytix Receives FDA Regulatory Clearance for Phage-Based E. coli Technology

Intralytix, Inc. announced today that it has received regulatory clearance from the Food and Drug Administration for its phage-based EcoShield™ food safety product, effective against E. coli O157:H7.

Intralytix Wins Army Grant To Develop A Phage-Based Probiotic To Manage Shigella Infections

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

Intralytix Wins Army Grant To Develop A Phage-Based Probiotic To Manage Shigella Infections

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

Intralytix Receives a Phase I U.S. Army grant supporting the development of a phage-based product for treating wounds infected with Acinetobacter baumannii.

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a phage-based product.

Intralytix Wins Army Grant for Salmonella and Shigella Technology

Intralytix, Inc. announced today that it has been awarded a contract from the U.S. Army to develop a bacteriophage-based food safety product.

Intralytix Wins Army Grant to develop a bacteriophage-based food safety product for reducing or eliminating contamination from pathogenic Salmonella and Shigella spp.

Intralytix, Inc. announced today that it has been awarded a contract from the U.S. Army to develop a bacteriophage-based food safety product for reducing or eliminating contamination from pathogenic

Intralytix awarded patent by USPTO for Bacteriophage treatment of colonization by pathogen bacteria, including MRSA

Intralytix, Inc., announced today that it has been issued a patent by the U.S. Patent & Trademark Office covering the use of bacteriophages to reduce the risk of bacterial infection including MRSA.

Intralytix wins Phase III Army grant for E. Coli technology

Intralytix, Inc., announced today that it has been named a recipient of a 2009 Army Commercialization Pilot Program (CPP) grant to support a phage-based technology development

Intralytix Wins Popular Science "Best of What's New" Award for its food safety product ListShield™

Intralytix, Inc., announced today that it has won the Popular Science "Best of What's New" award for its food safety product ListShield™.

FDA approves Intralytix's Food Safety Product (LMP 102)

Intralytix, Inc. announced today that the Food and Drug Administration has approved LMP 102 for use on ready-to-eat food.

Nov 30, 2022
On November 30, 2022, H.C. Wainwright & Co., LLC hosted the First Annual Bacteriophage Conference to highlight what H.C. Wainwright & Co. believes to be a major pending inflection point in the field. Intralytix was one of the phage companies featured at the conference, with our President and CEO, Dr. Alexander "Sandro" Sulakvelidze presenting.

Mar 02, 2022
Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.

Jan 12, 2022
Bacteria-killing viruses, called bacteriophages, are increasingly being used to destroy harmful microbes during food processing, to stop food rotting and to treat plant and animal diseases on farms.

Oct 27, 2021
Every year, one in seven people in America comes down with a foodborne illness, typically caused by a bacterial pathogen, including E.Coli, listeria, salmonella, or campylobacter

Sep 07, 2021
By harnessing the natural power of these bacteriophages, Intralytix offers robust food safety products designed to target some of the deadliest foodborne bacterial pathogens, including L. monocytogenes and E. coli.

Jun 01, 2021
An interview with Alexander "Sandro" Sulakvelidze, President and CEO of Intralytix, Inc.

May 11, 2021
Intralytix was given a "Positive" Lux Take by Lux Research in its report to its subscribing membership.

May 07, 2021
Maryland is a hotspot for research and production of superbug-killing bacteriophages.

Mar 16, 2021
If you thought food poisoning was just a matter of the occasional stomach upset from a dodgy shrimp or two, the CDC has some unsettling numbers for you.

Jun 16, 2020
Intralytix, the largest food safety phage company in the world, sits on the precipice of substantial growth and success. 23 years of building unrivaled bacteriophage expertise, developing and securing 15 issued patents, and being one of two phage companies in the world with sales revenue have put this Columbia, Maryland-based company in a position to harness several positive macro-market forces to fuel its expansion.

Feb 08, 2019
Intralytix, Inc.'s EcoActive™ bacteriophage therapy targeting adhesive invasive E. coli (AIEC) in Crohn's disease patients has entered a Phase 1/2a clinical trial.

Feb 07, 2019
Intralytix is holding a contest for the creation of cartoon characters depicting bacteriophages.

Nov 29, 2017
Intralytix, Inc. receives a U.S. Army award in support of studies on elucidating the interaction of bacteriophages with bacteria in various food matrixes and selected food safety interventions on the food microbiome.

Nov 27, 2017
Intralytix, Inc. announced that it has entered into a collaboration agreement for developing bacteriophage preparations against selected bacterial pathogens.

Sep 17, 2017
Bacteriophages: Nature's Answer to Killing Pathogens in Fresh Pet Food.

Jun 28, 2017
In the most recent report, Lux rated Intralytix as superior in 8 out of 10 categories used to rank the competitive companies.

Apr 18, 2017
Intralytix Inc's product targeting Shigella has received GRAS (Generally Recognized As Safe) recognition from the US Food and Drug Administration (FDA).

Nov 28, 2016
FDA on a Witch Hunt Against Commercial Pet Food? A Little Spritz of This Makes Pet Food Far Safer.

Mar 28, 2016
Intralytix wins grant from the U.S. Department of Agriculture to develop a phage cocktail that will be effective against the pathogens that kill larval shellfish.

Aug 25, 2015
Intralytix is exhibited at the World Congress on Beneficial Microbes in Valencia, Spain

Mar 15, 2015
Seafood Expo North America/Seafood Processing North America (SENA) March 15-17, 2015 Intralytix at the SENA, Boston Convention & Exhibition Center, Boston, MA, USA

Feb 13, 2015
Intralytix Receives Additional Regulatory Clearance for SalmoFresh™ - Phage-Based Food Safety Product Effective Against Salmonella.

Dec 12, 2014
Health Canada December 12, 2014 Health Canada approved the use of ListShield™ as a processing aid for ready-to-eat meat and poultry, smoked salmon, fresh-cut apples, and long leaf lettuce

Oct 31, 2014
Health Canada October 31, 2014 Health Canada approved the use of ListShield™ as a processing aid for ready-to-eat meat and poultry

Oct 16, 2014
Health Canada October 16, 2014 Health Canada approved the use of EcoShield™ as a processing aid for red meat

Aug 26, 2014
Health Canada August 26, 2014 Health Canada approved the use of SalmoFresh™ as a processing aid for various foods in Canada, in all jurisdictions recognized by Health Canada for the purposes of the iLONO policy

Aug 03, 2014
National Food Service, Ministry of Health, Tel Aviv, Israel August 3, 2014 Guidelines: Use of Bacteriophages (bacteria killing viruses) in Food (Ref: 70275202)

May 01, 2014
Baltimore Business Journal May, 2014 Baltimore Business Journal recognized Intralytix as one of the top 25 biotechnology companies in 2014

Mar 01, 2014
Discover Magazine March, 2014 Infections Infected

Mar 20, 2013
Food Safety News March 20, 2013 New Spray Product Takes Aim at Salmonella on Poultry

Feb 01, 2013
Environmental Health Perspectives February 1, 2013 Phage Renaissance: New Hope against Antibiotic Resistance

Apr 19, 2012
Miller-McCune April 19, 2012 Defeating Bacteria From the Inside Out

Apr 01, 2012
Bacteriophage April 1, 2012 The strange history of phage therapy

Sep 28, 2011
The Mark Steiner Show September 28, 2011 Urbanite Radio Story: Healing Waters

Aug 29, 2011
Urbanite August 29, 2011 Healing Waters: In the Inner Harbor, the seeds of a medical breakthrough

May 09, 2011
Food Safety News May 9, 2011 Food Pathogen Interventions: Phasing in Phages

Mar 22, 2011
Food Safety News March 22, 2011 Company Develops Natural Way to Fight E. coli

Dec 03, 2010
Journal of the American Veterinary Medical Association December 3, 2010 Searching for self-replicating antimicrobials

Sep 27, 2010
Los Angeles Times September 27, 2010 In The Works:? New Ways to Fight Bacteria

Oct 16, 2009
Gazette.Net Maryland Community Newspapers October 16, 2009 BioWatch: Baltimore biotech turns to the past for cutting-edge treatment

Apr 04, 2008
National Public Radio - April 4, 2008 Using 'Phage' Viruses to Help Fight Infection NPR Talk of the Nation:  Science Friday with Intralytix Vice President, Alexander Sulakvelidze

Apr 23, 2007
New York News - April 23, 2007 Spray to quell E. coli Baltimore company seeking FDA approval for viral substance to kill the bacteria on produce, raw meat

Oct 09, 2006
CBS News Video Spray For Bacteria-Free Meat Scientists in Baltimore, Maryland are harnessing billions of microscopic organisms in a war against bacteria such as E. coli, listeria and salmonella

Sep 19, 2006
CNN Video - September 19, 2006 Dr. Sanjay Gupta on the recent FDA approval of ListShield

Aug 19, 2006
PRESS RELEASE - August 19, 2006 FDA approves Intralytix's Food Safety Product (LMP 102)

Feb 01, 2006
Seed Magazine - Feb/Mar, 2006 Trail Phage Why antibiotics are so 1990's and how their complement may be squelched by the FDA

Dec 28, 2004
CRC Press - December 28, 2004 Bacteriophages: Biology and Applications 528 page book provides a comprehensive overview of phage history, biology, techniques, and applications

Oct 27, 2003
"Our World" Broadcast featuring Intralytix In the never-ending battle against bacterial infection

Oct 27, 2003
Voice of America - VOA News.com, October 27, 2003 "Our World" Broadcast featuring Intralytix In the never-ending battle against bacterial infection, antibiotics have been the main line of de

Mar 31, 2003
LA Times, March 31, 2003 Enlisting viruses to battle bacteria As even the most potent antibiotics lose the upper hand against bacteria, researchers are again exploring the potential of bacteriophage .

Oct 25, 2002
Bacteriophage therapy, pioneered in Stalin-era Russia, is attracting renewed attention in the West as a potential weapon against drug-resistant bugs and hard-to-treat infections

Sep 20, 2002
CBS News - 48 Hours, September 20, 2002 Silent Killers: Fantastic Phages? (CBS) After breaking his foot five years ago, Toronto bass player Alfred Gertler got an infection that antibiotics couldn't cure

Jan 07, 2002
Washington Techway, January 7, 2002 "Beating Superbugs" After years of research, phage therapy inches closer to market

Dec 01, 2001
Newsweek International, December, 2001 "Superbug Killers" Western scientists discovered a potent weapon against antibiotic-resistant bacteria in an unlikely place . . .

Dec 01, 2001
US News & World Report, December, 2001 "Infectious Arms Race" Forging new weapons against resurgent bacterial killers

Sep 01, 2001
FoodTech Source, September, 2001 "Phage-Enhanced Food Safety"

Jul 01, 2001
Agricultural Research Magazine, July, 2001 "Turning the Phage on Produce Pathogens" Tiny viruses, called phages, infect and kill bacteria naturally . . .

Oct 01, 2000
Smithsonian Magazine, October, 2000 "The Return of the Phage" As deadly bacteria increasingly resist antibiotics, researchers try to improve a World War I era weapon . . .

Jun 03, 2000
Science Service, Inc., June 3, 2000 "Viruses That Slay Bacteria Draw New Interest"

Jun 01, 2000
McMahonMed, June 20, 2000 "Viruses Called Bacteriophages Resurface As Viable Option To Fight Infections" See entire story

Mar 13, 2000
Washington Techway, March 13, 2000 "Planning for the day antibiotics fail" (Intralytix Inc's bacteriophage research plans)

Feb 06, 2000
New York Times, February 6, 2000 "A Stalinist Antibiotic Alternative"

Jan 21, 2000
DoubleTwist, January 21, 2000 "The return of bacteriophage therapies"

Technology

Food Safety

Environmental Sanitation

Veterinary Applications

Human Therapeutics

Probiotics